Backgrounds/Aims: Hepatocellular carcinoma (HCC) is uncommon in young adults and the prognosis of these patients is still unclear. In this retrospective study, we compared the clinicopathological characteristics and outcomes of young patients with HCC with those of older patients with HCC. Methods: We retrospectively reviewed the clinicopathological characteristics of a total of 1,124 patients with HCC who underwent hepatectomy at our institution between 2006 and 2010. Patients ≤40 years of age at the time of HCC diagnosis were classified in the younger group. Results: One hundred and three patients (9.2%) were classified in the younger group. whereas, 1021 patients were classified in the older group. The incidences of hepatitis B virus infection, alpha-fetoprotein (AFP) levels, and indocyanine green retention test were all higher in younger patients than in older patients (p＜0.05). Disease-free survival and overall survival were longer in older patients than in younger patients, without statistical significance. In younger patients, increased levels of protein induced by vitamin K antagonist-II (PIVKA-II) and alkaline phosphatase, portal vein tumor thrombosis, and intrahepatic metastasis were all predisposing factors for tumor recurrence after hepatectomy. Conclusions: Although the AFP levels were higher in younger patients with HCC than in older patients with HCC, disease-free survival and overall survival after liver resection were not significantly different between the two groups. 
INTRODUCTION
Hepatocellular carcinoma (HCC) is a common malignancy worldwide. Although HCC is generally diagnosed in middle-aged and elderly individuals, the age of peak incidence differs substantially according to etiology and geographical region. In low-risk areas of western countries, HCC is rarely diagnosed in patients younger than 40 years of age. However, in high-risk areas such as East Asia, HCC is often diagnosed in individuals aged between 20 to 40 years. 1 Therefore, HCC is a serious threat to public health in East Asia.
Patient age at the time of diagnosis has important prognostic value for certain cancers. While the prognosis for thyroid cancer is favorable if the patient is diagnosed at a young age, 2 this is an unfavorable prognostic factor for breast cancer. 3 The impact of diagnosis at a young age on the outcome of HCC remains controversial. This controversy could be due to geographic variability and differences in risk profiles between populations. [4] [5] [6] [7] [8] Several reports described the factors associated with poor prognosis for young patients with HCC. Most of these studies included patients with advanced disease at presentation and high serum alpha-fetoprotein (AFP) levels. 4, 6, 8 However, the difference in prognosis between young and old patients with HCC is not definitively established. There are several reports of worse outcomes for younger patients with HCC, as compared with older patients with HCC; 5, 7 whereas, others have reported no differences in survival between these two groups. 4, 6, 8 In this study, we compared the clinicopathological characteristics and outcomes of younger patients with HCC with those of older patients with HCC treated at our institution. 
MATERIALS AND METHODS

Patients
Gender (Male) Age (years) Etiology HBV HCV Alcohol NBNC Others AFP ≥200 (ng/ml) PIVKA-II ≥200 (mAU/ml) White blood cells (×10 3 /l) Hemoglobin (g/dl) Platelet (×10 3 /l) Prothrombin time (INR) Albumin (g/dl) Total bilirubin (mg/dl) AST (U/L) ALT (U/L) ALP (U/L) Creatinine (mg/dl) ICG-R15 (%)
RESULTS
Preoperative patient characteristics
The demographic and preoperative characteristics of the patients were shown in Table 1 . A total of 10.2% of the patients with HCC were classified in the young group.
The ratio of males to females in the younger group was not significantly different from that of the older group.
The younger group showed a higher incidence of HBV infection than the older group (89.3% vs. 79.9%); however, the incidences of non-B, non-C in the younger group were lower than in the older group (7.8% vs. 14.4%).
The mean AFP level in the younger group was higher than in the older group (5885.3±19750.5 ng/ml vs. There was no mortality after treatment among patients in the younger group (Table 2) .
Perioperative and pathological characteristics
Disease-free and overall survival
The mean follow-up duration in the younger and older groups were 35±18 months and 32.3±16.7 months, respectively (p=0.156). The 1-year, 2-year and 3-year disease-free survival rates were 65.5%, 53.9%, and 44.6% in the younger group, and 72.5%, 62.1%, and 57.3% in the older group, respectively. Disease-free survival in the younger group was lower than in the older group, without statistical significance (p=0.071) (Fig. 1) . The 1-year, 2-year, and 3-year overall survival rates were 93.1%, 
Tumor recurrence
Tumor recurrence was observed in 52 (50.5%) younger patients and 402 (39.7%) older patients. Intrahepatic recurrence occurred in 31 (59.6%) younger patients and 239
(59.5%) older patients. The differences in systemic recurrence (n=5, 9.6% vs. n=49, 12.2%) and concurrent intrahepatic and systemic recurrence (n=16, 30.8% vs.
n=114, 28.4%) between the 2 groups were not significant.
The risk factors for HCC recurrence after hepatectomy in the younger group were summarized in Table 3 .
Multivariate analysis revealed that increased PIVKA-II levels, increased ALP levels, portal vein tumor thrombosis, and intrahepatic metastasis were independent predisposing factors for tumor recurrence.
DISCUSSION
The prognosis of young adults with HCC is controversial.
In the present study, younger patients with HCC who underwent hepatectomy were more likely than older patients to be HBV-positive, to have high AFP levels at diagnosis, and better liver function status. However, tumor size, tumor number, serum PIVKA-II levels at presentation and extent of liver resection were not significantly different in younger patients, as compared to older patients. Therefore, the survival outcomes of young adults with HCC are not measurably different from those of older patients after liver resection.
The outcome of young patients with HCC is highly debated. Among the tumor factors, AFP levels are reportedly higher in younger patients than older patients.
Specifically, more than 50% of all patients with HCC are shown to have an AFP level equal to or exceeding 400 ng/ml. 5, 6, 14 In addition, younger patients tend to have larger tumors than older patients, with the maximum tumor diameter in younger patients exceeding 6 cm. 6, 8, 14, 15 Thus, younger patients with HCC should be offered aggressive hepatectomy to preserve liver function. In the present study, the younger group had higher AFP levels and showed better liver function than the older group; these findings are consistent with previous reports. 6, 14, 15 However, tumor size did not differ significantly between the 2 groups. In addition, the presence of initial metastases was similar between the 2 groups. Specifically, younger patients with HCC had worse disease-free and overall survival rates, presumably because they presented with higher AFP levels. However, the survival rates of younger and older patients were not significantly different. Therefore, the natural histories of younger patients with HCC may be similar to those of older patients with HCC after hepatectomy. Thus, early detection may be the best way to improve the prognosis of young patients.
Previous studies have reported that young patients with HCC (aged ＜40 years) tend to have poor prognoses, as compared to older patients. This is most likely because young patients are often diagnosed at more advanced stages of disease, as indicated by their high serum AFP levels and advanced TNM stages. 4, 6, 8 The results of our study are consistent with previous reports on the importance of higher serum AFP levels; however, we did not find any significant differences in disease-free or overall survival between younger and older patients with HCC.
In addition, high serum AFP levels were not associated with tumor recurrence in younger patients.
We defined younger patients with HCC as patients less than 40 years of age at the time of HCC diagnosis. In the present study, 10.2% of all patients with HCC were classified as younger patients. The present study had some limitations. First, the signs and symptoms of the patients with HCC were not included in the clinical data because it was impossible to identify these warning signs or symptoms for early detection in young patients. Second, the detailed treatment records taken at the time when young patients experienced HCC recurrence did not include sufficient data for analysis. It was difficult to collect treatment data for patients with recurrent HCC because many of these patients were treated at other centers. Third, since the observational data were analyzed at a single institution, there was possible selection bias; specifically, younger patients may have been more likely to be referred to our institution for evaluation and treatment, while older patients may have received less aggressive treatments and had lower referral rates. In support of this idea, older patients are often managed at community centers. Fourth, patients with unresectable HCC were not included in our analysis. Our study focused on patients who underwent hepatectomy, and its results may therefore have been biased.
In conclusion, younger patients with HCC have different clinical characteristics than older patients with HCC.
Specifically, younger patients with HCC are more likely to have hepatitis B infection, high AFP levels, and better liver function. However, younger and older patients with HCC after surgical resection did not exhibit any significant differences regarding disease-free survival and overall survival.
